BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral ...

And two weeks ago, the FDA officially proposed removing it as an active ingredient in oral over-the-counter drugs for nasal ...

A research team has developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain. This groundbreaking innovation offers a safe, non-opioid-based solution for conditions ...

The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin that drives childbirth contractions.

In 2023, the then 49-year-old went to her physician with painful headaches, blurring vision, pain and swelling of her eyes ...

A mother says years of painful headaches and speech issues from brain tumors were caused by prolonged use of a Pfizer birth ...

U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...

This medication is a calcium channel blocker, prescribed for high blood pressure and chest pain. It widens blood vessels and improves blood flow by not making the heart pump harder. It widens ...